PhD | Protein-based Therapy: Embark on a transformative journey in cancer treatment research with the PhD opportunity in “Protein-based Chelators for Targeted Radionuclide Therapy.” This project, commencing March 5th, 2024, explores innovative approaches to enhance the development of radiopharmaceuticals for targeted cancer treatment. As a prospective candidate, you have the chance to contribute to groundbreaking advancements in cancer therapy by integrating protein-based alternatives into the production process, providing new possibilities for targeted radionuclide therapy.
PhD | Protein-based Chelators for Targeted Radionuclide Therapy
Summary Table:
| Application Start Date | March 5th, 2024 |
|---|---|
| Duration | 4 years |
| Expert Group | RadioPharma Research |
| SCK CEN Mentor | Rob Van Houdt, rob.van.houdt@sckcen.be, +32 (0)14 33 27 28 |
| SCK CEN Co-mentor | Kristel Mijnendonckx, kristel.mijnendonckx@sckcen.be, +32 (0)14 33 21 06 |
| Promoter | Joleen Masschelein, joleen.masschelein@kuleuven.be, Katholieke Universiteit Leuven (KU Leuven) |
Study Area: The project focuses on the development of radiopharmaceuticals for targeted radionuclide therapy, specifically exploring protein-based chelators as alternatives to synthetic chemical chelators. The study intersects the fields of Biology, (Bio)chemistry, and Bio-engineering, offering a unique opportunity to contribute to advancements in cancer treatment.
Scholarship Description: The PhD project aims to enhance the development of radiopharmaceuticals by implementing and benchmarking protein-based alternatives to conventional synthetic chemical chelators. These protein-based alternatives will be directly fused to proteinous carriers, such as peptides or nanobodies, produced recombinantly, and rigorously benchmarked. The research provides a platform for innovation and exploration in targeted radionuclide therapy.
Eligibility: Prospective candidates must hold a Master of Sciences degree with a background in Biology, (Bio)chemistry, or Bio-engineering. The project welcomes individuals with a passion for advancing cancer treatment and exploring novel approaches in the field.
Required Documents: Before applying, candidates are advised to consult the guidelines for the application. Specific document requirements will be detailed in the application guidelines.
How to Apply: Commencing from March 5th, 2024, interested candidates can apply for this PhD opportunity via the provided link. For detailed application guidelines, prospective applicants are encouraged to review the guidelines provided.
Last Date: The deadline for submission is to be announced. Ensure to submit your application before the deadline to be part of this cutting-edge research endeavor in cancer treatment.
